Sign In
Buy PBYI
$6.81
-0.170 (-2.44%)
At Close: Jun 03, 2026
Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference
04:10pm, Tuesday, 21'st Sep 2021
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present an overview of Puma Biotechnology at 8:00 a.m. EDT on Sept. 28, at the 2021 Cantor Virtual Global Healthcare Conference.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Tuesday, 07'th Sep 2021
LOS ANGELES--(BUSINESS WIRE)--On Sept. 7, 2021, Puma Biotechnology reported inducement awards granted to new staff in August, as required by Nasdaq Listing Rule 5635(c)(4) .
Puma Bio: Recent Sell-Off Brings My Position Out Of Mothball
01:17am, Friday, 13'th Aug 2021
Puma Bio: Recent Sell-Off Brings My Position Out Of Mothball
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:50pm, Friday, 06'th Aug 2021
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards granted for July 2021 new hires, as required by Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q2 2021 Results - Earnings Call Transcript
10:55pm, Thursday, 05'th Aug 2021
Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q2 2021 Results - Earnings Call Transcript
Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates
10:03pm, Thursday, 05'th Aug 2021
Puma Biotech (PBYI) delivered earnings and revenue surprises of 58.06% and 4.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital
08:33am, Monday, 26'th Jul 2021
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology and Athyrium Capital have entered into an agreement for the issuance of up to $125 million of notes in two tranches.
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
04:15pm, Thursday, 22'nd Jul 2021
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PT on Aug. 5 following the release of its second quarter 2021 financial results.
Puma Biotech's Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast Cancer
10:23am, Tuesday, 06'th Jul 2021
Health Canada has approved Puma Biotechnology Inc's (NASDAQ: PBYI) Nerlynx (neratinib) in combination with capecitabine for metastatic HER2-overexpressed/amplified breast cancer, who have received t
Knight Therapeutics Announces Health Canada Approval for NERLYNX® (Neratinib) to Treat HER2-Positive Metastatic Breast Cancer
08:00am, Tuesday, 06'th Jul 2021
MONTREAL, July 06, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approve
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:15pm, Friday, 02'nd Jul 2021
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the grant of inducement restricted stock unit awards in June 2021, as required by Nasdaq Listing Rule 5635(c)(4) .
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology received FDA approval to include dose escalation in the NERLYNX label for both early stage and metastatic breast cancer patients.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Friday, 04'th Jun 2021
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reports inducement awards granted in May 2021 as required under Nasdaq Listing Rule 5635(c)(4) .
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented data from the EGFR Exon 18-mutant NSCLC cohort of the Phase II SUMMIT Trial on June 4 at the 2021 ASCO Annual Meeting.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented data from the Phase II CONTROL Trial regarding neratinib dose escalation at the ASCO 2021 Annual Meeting.
